---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-24-001573"
form_type: "8-K/A"
ticker: null
cik: "0001708331"
company_name: "Virpax Pharmaceuticals, Inc."
filed_at: "2024-10-09T23:59:59+00:00"
generated_at: "2026-05-30T17:24:16.870381+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Virpax CEO & CFO resign amid disagreements; Nasdaq warns of bid price deficiency

## Summary
- CEO Gerald Bruce and CFO Vinay Shah resigned Oct 5, citing disagreements with Board's execution of policies.
- Board appointed director Jatinder Dhaliwal as new CEO effective Oct 6; Katharyn Field replaces him on audit committee.
- Nasdaq notified company Oct 4 that bid price below $1.00 for 30 consecutive days; 180-day cure period until Apr 2, 2025.
- Company disagrees with allegations in Bruce's resignation letter, filed as exhibit.
- If not compliant by Apr 2, 2025, may get second 180-day period; delisting risk if not cured.

## SEC filing metadata
- accession: 0001731122-24-001573
- form_type: 8-K/A
- cik: 0001708331
- company_name: Virpax Pharmaceuticals, Inc.
- filed_at: 2024-10-09T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708331/000173112224001573/0001731122-24-001573-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708331/000173112224001573/e6017_8-ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-24-001573
- JSON: https://secwatch.observer/filing/0001731122-24-001573.json
- Plain text: https://secwatch.observer/filing/0001731122-24-001573.txt

## Key facts
- Executive change
  Jatinder Dhaliwal was appointed as Chief Executive Officer at Virpax Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On October 6, 2024, the Board appointed Jatinder Dhaliwal, a member of the Board, to serve as Chief Executive Officer of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708331/000173112224001573/0001731122-24-001573-index.htm
- Executive change
  Gerald Bruce resigned as Chief Executive Officer at Virpax Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: On October 5, 2024, Gerald Bruce, as Chief Executive Officer and member of the Board of Directors (the “Board”), and Vinay Shah, as Chief Financial Officer, notified the Company of their resignation from their respective positions, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708331/000173112224001573/0001731122-24-001573-index.htm
- Executive change
  Gerald Bruce resigned as Director at Virpax Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Director
  source text: On October 5, 2024, Gerald Bruce, as Chief Executive Officer and member of the Board of Directors (the “Board”), and Vinay Shah, as Chief Financial Officer, notified the Company of their resignation from their respective positions, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708331/000173112224001573/0001731122-24-001573-index.htm
- Executive change
  Vinay Shah resigned as Chief Financial Officer at Virpax Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On October 5, 2024, Gerald Bruce, as Chief Executive Officer and member of the Board of Directors (the “Board”), and Vinay Shah, as Chief Financial Officer, notified the Company of their resignation from their respective positions, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708331/000173112224001573/0001731122-24-001573-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.